ifa systems AG
- WKN: 783078
- ISIN: DE0007830788
- Land: Deutschland
Nachricht vom 04.06.2019 | 10:50
ifa systems AG: Nexus AG acquires majority participation in ifa systems AG from Topcon
ifa systems AG / Key word(s): Investment
The majority shareholder of ifa systems AG, Topcon Europe Medical B.V., has informed the management board that it has entered into a share purchase agreement on the disposal of its participation in ifa systems AG amounting to approx. 52.56 % of the share capital with Nexus AG having its seat in Donaueschingen. The share purchase agreement will be consummated by 5 June 2019 the latest. The loans granted to ifa systems AG by Topcon in the amount of EUR 4m will be assumed by Nexus AG in the amount of EUR 3m and repaid by ifa systems AG in the amount of EUR 1m. Such repayment will not reduce the cash since it will be set-off against payment claims of ifa group against Topcon. In the course of the transaction, the supervisory board members Nick Smit and Randy Samuels as well as the management board member Nobuo Takase will also resign from their offices by 5 June 2019 the latest with immediate effect. The management board will apply for the appointment of two new supervisory board members by court at short notice.
Contact (informing person):
|Company:||ifa systems AG|
|Augustinusstraße 11 b|
|Phone:||+49 (0)2234 93367-0|
|Fax:||+49 (0)2234 93367-30|
|Listed:||Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||818893|
|End of Announcement||DGAP News Service|
ifa systems AG: ifa systems successfully compl ...
ifa systems AG: ifa systems strengthens its co ...
ifa systems AG: ifa systems acquires majority ...
ifa systems AG: ifa systems acquires a majorit ...
ifa systems confirms the very good year 2019
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
03. Dezember 18:19 Musterdepot-Titel BHP: Es geht voran
03. Dezember 19:02 Dow Jones: Es hört nicht auf...
03. Dezember 19:50 Commerzbank und Deutsche Bank: "Bitte keine großzügige ...
03. Dezember 20:20 Apple unter Druck – aber die Lage hellt sich langsam auf
03. Dezember 21:33 Schlussglocke: Dow Jones schließt schwache Woche mit weiterem Minus ab
News im Fokus
Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an
03. Dezember 2021, 07:03
FY 2020/2021 Financial Results
16. Dezember 2021
Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen
02. Dezember 2021